691875-76-0

Upstream product

• 405-50-5 p-Fluorophenylacetic acid 
• 51230-93-4 2-(4-fluorophenyl)pent-4-enoic acid 
• 85068-29-7 3,5-bis-trifluoromethylbenzylamine 
• 494802-92-5 (S)-2-(4-fluorophenyl)-4-pentenoic acid 

Downstream Products

• 691873-56-0 N-(3,5-bis-trifluoromethyl-benzyl)-2-(4-fluoro-phenyl)-4-(4-phenyl-piperidin-1-yl)-butyramide 
• 903512-73-2 (S)-2-(4-Fluoro-phenyl)-5-oxo-pentanoic acid 3,5-bis-trifluoromethyl-benzylamide 
• 913537-21-0 (S)-2-(4-Fluoro-phenyl)-5-hydroxy-pentanoic acid 3,5-bis-trifluoromethyl-benzylamide 
• 903512-72-1 N-(3,5-bis-trifluoromethyl-benzyl)-2-(4-fluoro-phenyl)-4-oxo-butyramide 

Relevant academic research and scientific papers

Novel, orally bioavailable γ-aminoamide CC chemokine receptor 2 (CCR2) antagonists

Through modification of a screening hit we have discovered a structurally distinct new lead, (2S)-N-[3,5-bis(trifluoromethyl)benzyl]-2-(4-fluorophenyl)-4- (4-phenylpiperidin-1-yl)butanamide (11), which has subsequently served as the departure point for an

GAMMA-AMINOAMIDE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to compounds of the formula (I), wherein R1, R2, R3, R4, R5, R6, R7, R8, R11, R12, W, X, and n are defined herein, which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.